19:24 , Feb 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Mouse studies suggest CRYAB could help treat peripheral nerve damage. In a mouse model of sciatic nerve damage, human CRYAB increased remyelination of the sciatic nerve and mechanical sensitivity and decreased gait...
08:00 , Nov 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Crystallin α B (CRYAB; HSPB5)

Ophthalmic disease In vitro, mouse and patient sample studies suggest a chaperone of CRYAB could help treat cataract. A differential scanning fluorometry-based screen on a small molecule library identified a lead compound that decreased formation...
08:00 , Nov 12, 2015 |  BC Innovations  |  Product R&D

Crystallin-clear ViewPoint

By exploring the biophysics of proteins with disease-associated mutations, a UCSF group has developed a way to screen for drugs that rescue the activity of non-enzymatic targets, and proved its value with molecular chaperones. After...
08:00 , Jan 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Dopamine D2 receptor In vitro and mouse studies suggest dopamine D2 receptor agonists could help treat neuroinflammation in diseases such as PD....
07:00 , Aug 16, 2012 |  BC Innovations  |  Targets & Mechanisms

Amyloids for inflammation

Researchers at Stanford University have found that systemic treatment with b-amyloid peptides can reduce inflammation and reverse paralysis in mouse models of multiple sclerosis. 1 Cardinal Therapeutics Inc. has licensed the work and now is...
08:00 , Mar 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Crystallin aB (CRYAB; HSPB5) In vitro studies identified a mechanism for HSPB5's anti-inflammatory activity that could help improve treatment of multiple sclerosis (MS). HspB5...
07:00 , Jul 3, 1995 |  BC Week In Review  |  Company News

Netherlands Institute for Brain Research other research news

Researchers have identified a key antigenic molecule in the immune attack on the nervous system that causes multiple sclerosis. As reported in Nature, the scientists tested the responses of primed human T cells against fractions...